U.S. Markets open in 9 hrs 25 mins

Pixium Vision highlights its latest progress and achievements in its Annual General Meeting 2019

Paris, May 29, 2019 – 06:00 PM CEST - The Annual General Meeting of Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, was held in Paris on May 29, 2019 and adopted all the proposed resolutions..

Lloyd Diamond, newly appointed Chief Executive Officer introduced himself to shareholders and stated: “I am particularly happy to join Pixium Vision and my initial interaction with the team has been outstanding. We have a committed team of bright and motivated engineers developing our breakthrough technology platform. My first goal is to enhance the strategy in order to fully unlock PRIMA’s value in the dry Age-related Macular Degeneration (AMD), a major unmet clinical need.”

In the course of its Annual General Meeting, Pixium Vision gave an update on the latest progress of the clinical development of its bionic vision system PRIMA. The five implanted patients in France are pursuing their rehabilitation program. The 6-month results were positive on both the safety side and the performance of the implant eliciting visual perception in a retinal area without residual visual activity. Some patients are able to identify letters and the sequence of letters. The 5 patients 12-month follow-up results are expected before half-year.

In the United States, recruitments are still ongoing with the opening of a second investigational center, the Bascom Palmer Eye Institute in Miami (Florida), the highest ranked ophthalmology center in the United States.

Pixium Vision also continues to improve its bionic vision system notably with the delivery of its next generation transparent glasses. These glasses will enable AMD patients to combine both prosthetic and natural residual vision.

Technologies embedded in transparent glasses are truly innovative and protected by several patents, strengthening the intellectual property of Pixium Vision. In all, Pixium Vision has filed 25 patents in 2018 and is ranked among the most active companies in R&D in France as recorded by FrenchTech1. Its offensive intellectual property strategy enables Pixium Vision to protect its innovations and strengthen its value creation potential for its employees, its partners and its shareholders.

Finally, Pixium Vision has been awarded numerous prize2 of which the prestigious Galien Prize as well as the LetsGoFrance trophy awarding its international entrepreneurship. These awards are recognizing the value of the accomplishment by a talented pluri-disciplinary team and its partners, all committed to a truly innovative therapeutic project and commercially promising.


Contacts

Pixium Vision

 

Didier Laurens, CFO
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations
Newcap Media
Annie-Florence Loyer - afloyer@newcap.fr
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin - ljacquin@newcap.fr
+33 1 44 71 94 94
US Investor Relations
ICR
David Clair
david.clair@icrinc.com
+1 646 277 12 66

 

ABOUT PRIMA

PRIMA is a new generation miniaturized and totally wireless sub-retinal implant. The 2x2 millimeters wide and 30 microns thick photovoltaic chip contains 378 electrodes. Implanted under the retina via a minimally invasive surgical procedure, it acts like an array of tiny solar panel powered by pulsed near infrared light projected from a miniature projector integrated into augmented reality glasses, along with a mini camera. PRIMA is designed to restore sight in patients blinded by retinal dystrophies – a very significant unmet medical need. The target population includes patients with atrophic dry Age-related Macular Degeneration (dry AMD), and Retinitis Pigmentosa (RP). In addition to a clinical trial with five atrophic dry-AMD patients in France, PRIMA is approved for a similar five-patients study in USA.

ABOUT AGE-RELATED MACULAR DEGENERATION (AMD)

Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates1 for people living with AMD of around 196 million people worldwide and expected rapid growth due to ageing population. Around 1,000 new patients are diagnosed everyday just in Europe and USA. There are two forms of advanced AMD: the wet form, where treatment like anti-VEGF injections slows down the disease progression, and the dry form that is most frequent, where there is currently no curative treatment available. More than 5 million patients are afflicted with advanced dry AMD, also referred to as Geographic Atrophy. Patients suffering from this retinal dystrophy gradually lose their central vision (responsible for high visual acuity, e.g. for reading and face recognition) due to loss of photoreceptors.

ABOUT PIXIUM VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.


For more information, please visit:  www.pixium-vision.com;
And follow us on: @PixiumVision;  www.facebook.com/pixiumvision
               www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

  Pixium Vision is included in the Euronext CAC All Shares index   Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number D.19-0364 on April 18, 2019 which can be found on the websites of the AMF - AMF (www.amf-france.org

1 http://100brevets.tech/ (Top 10 April 2019)

2 Galien Prize 2018 – Research project; LetsGoFrance Trophy 2019 –France international standing; Embedded Trophy 2018 – Jury Special Prize

1 Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C. Y., & Wong, T. Y. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2(2), e106-e116 (https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext)


Attachment